ROCKVILLE, MD and SHENZHEN, CHINA, November 16, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive disease
November 17, 2022
Learn more
ROCKVILLE, MD and SHENZHEN, CHINA, October 25, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases
October 24, 2022
Learn more
ROCKVILLE, MD and SHENZHEN, CHINA , October 20, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,
October 20, 2022
Learn more
ROCKVILLE, MD and SHENZHEN, CHINA, October 14, 2022 HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,
October 14, 2022
Learn more
SHENZHEN, CHINA and ROCKVILLE, MD, August 30, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address th
August 30, 2022
Learn more
SHENZHEN, CHINA and ROCKVILLE, MD, April 28, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of me
April 28, 2022
Learn more
© 2020 HighTide Therapeutics Inc.